Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?

References

• Almåsbak H, Aarvak T, Vemuri MC. CAR T cell therapy: a game changer in cancer treatment. J Immunol Res. 2016. doi:10.1155/2016/5474602. Epub 2016 May 19.
   PubMed Web of Science ®Google Scholar
• Maus MV, June CH. Making better chimeric antigen receptors for adoptive T-cell THERAPY. Clin Cancer Res. 2016;22(8):1875–1884.
   PubMed Web of Science ®Google Scholar
• Weijtens ME, Willemsen RA, Valerio D, et al. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol. 1996;157(2):836–843.
   PubMed Web of Science ®Google Scholar
• Nolan KF, Yun CO, Akamatsu Y, et al. Bypassing immunization: optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res. 1999;5(12):3928–3941.
   PubMed Web of Science ®Google Scholar
• Hombach A, Muche JM, Gerken M, et al. T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30(+) cutaneous lymphoma cells. Gene Ther. 2001;8(11):891–895.
   PubMed Web of Science ®Google Scholar
• Maude S, Barrett DM. Current status of chimeric antigen receptor therapy for haematological malignancies. Br J Haematol. 2016;172(1):11–22.
   PubMed Web of Science ®Google Scholar
• Hombach AA, Görgens A, Chmielewski M, et al. Superior therapeutic index in lymphoma therapy: CD30(+) CD34(+) hematopoietic stem cells resist a chimeric antigen receptor (CAR) T cell attack. Mol Ther. 2016. doi:10.1038/mt.2016.82. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Lynn RC, Poussin M, Kalota A, et al. Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood. 2015;125(22):3466–3476.
   PubMed Web of Science ®Google Scholar
• Lynn RC, Feng Y, Schutsky K, et al. High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia. 2016. doi:10.1038/leu.2016.35. Epub 2016 Feb 22.
   PubMed Web of Science ®Google Scholar
• Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that reed-sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66(4):848–858.
   PubMed Web of Science ®Google Scholar
• Agrawal B, Reddish M, Longenecker BM. CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors. J Immunol. 1996;157(8):3229–3234.
   PubMed Web of Science ®Google Scholar
• von Wasielewski R, Mengel M, Fischer R, et al. Classical Hodgkin’s disease. Clinical impact of the immunophenotype. Am J Pathol. 1997;151(4):1123–1130.
   PubMed Web of Science ®Google Scholar
• von Wasielewski R, Werner M, Fischer R, et al. Lymphocyte-predominant Hodgkin’s disease. An immunohistochemical analysis of 208 reviewed Hodgkin’s disease cases from the German Hodgkin study group. Am J Pathol. 1997;150(6):1925–1932.
   PubMed Web of Science ®Google Scholar
• de Bruin PC, Gruss HJ, van der Valk P, et al. CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications. Leukemia. 1995;9(10):1620–1627.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Podda A, Prolla G, et al. CD30 in normal and neoplastic cells. Clin Immunol. 1999;90(2):157–164.
   PubMed Web of Science ®Google Scholar
• Latza U, Foss HD, Dürkop H, et al. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. Am J Pathol. 1995;146(2):463–471.
   PubMed Web of Science ®Google Scholar
• Dürkop H, Foss HD, Eitelbach F, et al. Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol. 2000;190(5):613–618.
   PubMed Web of Science ®Google Scholar
• Mechtersheimer G, Möller P. Expression of Ki-1 antigen (CD30) in mesenchymal tumors. Cancer. 1990;66(8):1732–1737.
   PubMed Web of Science ®Google Scholar
• Aggerholm-Pedersen N, Bærentzen S, Holmberg Jørgensen JP, et al. A rare case of CD30(+), radiation-induced cutaneous angiosarcoma misdiagnosed as T-cell lymphoma. J Clin Oncol. 2011;29(13):e362–364.
   PubMed Web of Science ®Google Scholar
• Schwarting R, Gerdes J, Dürkop H, et al. BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood. 1989;74(5):1678–1689.
   PubMed Web of Science ®Google Scholar
• Muta H, Podack ER. CD30: from basic research to cancer therapy. Immunol Res. 2013;57(1–3):151–158.
   PubMed Web of Science ®Google Scholar
• Abujarour R, Valamehr B, Robinson M, et al. Optimized surface markers for the prospective isolation of high-quality hiPSCs using flow cytometry selection. Sci Rep. 2013;3:1179.
   PubMed Web of Science ®Google Scholar
• Chung T-L, Turner JP, Thaker NY, et al. Ascorbate promotes epigenetic activation of CD30 in human embryonic stem cells. Stem Cells. 2010;28(10):1782–1793.
   PubMed Web of Science ®Google Scholar
• Mateizel I, Spits C, Verloes A, et al. Characterization of CD30 expression in human embryonic stem cell lines cultured in serum-free media and passaged mechanically. Hum Reprod. 2009;24(10):2477–2489.
   PubMed Web of Science ®Google Scholar
• Beckmann J, Scheitza S, Wernet P, et al. Asymmetric cell division within the human hematopoietic stem and progenitor cell compartment: identification of asymmetrically segregating proteins. Blood. 2007;109(6):5494–5501.
   PubMed Web of Science ®Google Scholar
• Dotti G, Gottschalk S, Savoldo B, et al. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107–126.
   PubMed Web of Science ®Google Scholar
• Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110(7):2620–2630.
   PubMed Web of Science ®Google Scholar
• Taussig DC, Pearce DJ, Simpson C, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005;106(13):4086–4092.
   PubMed Web of Science ®Google Scholar
• Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122(18):3138–3148.
   PubMed Web of Science ®Google Scholar
• Tettamanti S, Marin V, Pizzitola I, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013;161(3):389–401.
   PubMed Web of Science ®Google Scholar
• Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014;28(8):1596–1605.
   PubMed Web of Science ®Google Scholar
• Gill S, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123(15):2343–2354.
   PubMed Web of Science ®Google Scholar
• Liu X, Jiang S, Fang C, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 2015;75(17):3596–3607.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang QJ, Yang S, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol. 2009;183(9):5563–5574.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Hombach A, Heuser C, et al. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004;173(12):7647–7653.
   PubMed Web of Science ®Google Scholar
• Chen H-F, Yu C-Y, Chen M-J, et al. Characteristic expression of major histocompatibility complex and immune privilege genes in human pluripotent stem cells and their derivatives. Cell Transplant. 2015;24(5):845–864.
   PubMed Web of Science ®Google Scholar
• Zheng J, Umikawa M, Zhang S, et al. Ex vivo expanded hematopoietic stem cells overcome the MHC barrier in allogeneic transplantation. Cell Stem Cell. 2011;9(2):119–130.
   PubMed Web of Science ®Google Scholar
• El Haddad N, Moore R, Heathcote D, et al. The novel role of SERPINB9 in cytotoxic protection of human mesenchymal stem cells. J Immunol. 2011;187(5):2252–2260.
   PubMed Web of Science ®Google Scholar
• El Haddad N, Heathcote D, Moore R, et al. Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. Blood. 2011;117(4):1176–1183.
   PubMed Web of Science ®Google Scholar
• Utermöhlen O, Krönke M. Survival of priceless cells: active and passive protection of embryonic stem cells against immune destruction. Arch Biochem Biophys. 2007;462(2):273–277.
   PubMed Web of Science ®Google Scholar
• Abdullah Z, Saric T, Kashkar H, et al. Serpin-6 expression protects embryonic stem cells from lysis by antigen-specific CTL. J Immunol. 2007;178(6):3390–3399.
   PubMed Web of Science ®Google Scholar
• Sun J, Bird CH, Sutton V, et al. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem. 1996;271(44):27802–27809.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Terakura S, Martens AC, et al. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells. J Immunol. 2015;194(3):911–920.
   PubMed Web of Science ®Google Scholar
• Valitutti S, Müller S, Cella M, et al. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature. 1995;375(6527):148–151.
   PubMed Web of Science ®Google Scholar
• Huang J, Brameshuber M, Zeng X, et al. A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4(+) T cells. Immunity. 2013;39(5):846–857.
   PubMed Web of Science ®Google Scholar
• Sykulev Y, Joo M, Vturina I, et al. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity. 1996;4(6):565–571.
   PubMed Web of Science ®Google Scholar
• Hudecek M, Lupo-Stanghellini M-T, Kosasih PL, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013;19(12):3153–3164.
   PubMed Web of Science ®Google Scholar
• James SE, Greenberg PD, Jensen MC, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008;180(10):7028–7038.
   PubMed Web of Science ®Google Scholar
• Hombach A, Heuser C, Gerken M, et al. T cell activation by recombinant FcepsilonRI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition. Gene Ther. 2000;7(12):1067–1075.
   PubMed Web of Science ®Google Scholar
• Caruso HG, Hurton LV, Najjar A, et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 2015;75(17):3505–3518.
   PubMed Web of Science ®Google Scholar